| P2093 | author name string | Allan Lipton | |
| | Matthew R Smith | |
| | Georgiana K Ellis | |
| | Carsten Goessl | |
| P2860 | cites work | Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial | Q46847543 |
| | Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer | Q46884243 |
| | Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy | Q49133803 |
| | Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. | Q50709872 |
| | Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. | Q50758473 |
| | Reduced pulmonary function in patients with spinal osteoporotic fractures. | Q50859621 |
| | Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. | Q53591340 |
| | [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer] | Q57135645 |
| | Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial | Q57910396 |
| | Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q59567521 |
| | Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q59567527 |
| | Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group | Q59616816 |
| | The diagnosis of osteoporosis | Q72846752 |
| | Bisphosphonates: mechanisms of action | Q74291014 |
| | Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer | Q79422750 |
| | Chemoprevention of breast cancer with selective oestrogen-receptor modulators | Q79448439 |
| | Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial | Q79984455 |
| | The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy | Q80439595 |
| | Supportive care in oncology | Q81140727 |
| | Residual risk of breast cancer recurrence 5 years after adjuvant therapy | Q81769695 |
| | Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis | Q82526832 |
| | NCCN Task Force Report: Bone Health and Cancer Care | Q83885132 |
| | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group | Q28239579 |
| | Elimination mechanisms of therapeutic monoclonal antibodies | Q28297407 |
| | Osteoclast differentiation and activation | Q29547556 |
| | Abiraterone and increased survival in metastatic prostate cancer | Q29617512 |
| | Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis | Q29619487 |
| | Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. | Q31866905 |
| | Update in male osteoporosis | Q33586703 |
| | American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer | Q33631047 |
| | Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment | Q33736180 |
| | Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy | Q33787731 |
| | Osteoporosis due to cancer treatment: pathogenesis and management | Q33874458 |
| | Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. | Q33889548 |
| | Mechanisms of bone metastasis | Q33977526 |
| | Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer | Q33978286 |
| | Increased fracture rate in women with breast cancer: a review of the hidden risk | Q34004925 |
| | Excess mortality following hip fracture: a systematic epidemiological review | Q34017422 |
| | Update on Estrogens and the Skeleton | Q34031994 |
| | Sex steroids and the construction and conservation of the adult skeleton | Q34131889 |
| | Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy | Q34149575 |
| | Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. | Q34414177 |
| | Denosumab in men receiving androgen-deprivation therapy for prostate cancer | Q34570396 |
| | The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors | Q34617864 |
| | NCCN Task Force Report: Bone Health in Cancer Care | Q34617936 |
| | Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer | Q34617956 |
| | Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q34620634 |
| | Epidemiology and outcomes of osteoporotic fractures | Q34671295 |
| | Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer | Q34813227 |
| | Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study | Q34960850 |
| | Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer | Q35569309 |
| | Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies | Q35675197 |
| | Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study | Q42829926 |
| | Long term zoledronic acid during androgen blockade for prostate cancer. | Q43010770 |
| | Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. | Q43073125 |
| | The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis | Q43123333 |
| | Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. | Q43197341 |
| | Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy | Q43275775 |
| | Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. | Q43745339 |
| | Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer | Q43749401 |
| | Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status | Q43872799 |
| | A comparison of international breast cancer guidelines - do the national guidelines differ in treatment recommendations? | Q44228964 |
| | Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer | Q44456773 |
| | Bone loss and bone size after menopause | Q44524236 |
| | American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer | Q44578291 |
| | Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer | Q44836371 |
| | Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer. | Q44847641 |
| | Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition | Q44958689 |
| | Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial | Q45006027 |
| | Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors | Q45211867 |
| | Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. | Q46016026 |
| | Medical oncology: zoledronic acid prevents bone loss in early-stage breast cancer | Q46068357 |
| | Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study | Q46077710 |
| | A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women | Q46133598 |
| | Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. | Q46336448 |
| | Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid | Q46570802 |
| | Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. | Q46726174 |
| | Bisphosphonate treatment recommendations for oncologists | Q46786815 |
| | Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. | Q46801197 |
| | Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases | Q46802463 |
| | Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States | Q35855513 |
| | Long-term implications of bone loss in breast cancer | Q35976780 |
| | Skeletal health in postmenopausal survivors of early breast cancer. | Q36006750 |
| | Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension | Q36153179 |
| | Androgen deprivation therapy for prostate cancer | Q36193125 |
| | Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells | Q36230062 |
| | Cancer-treatment-induced bone loss, part 2. | Q36416064 |
| | Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update | Q36490774 |
| | Bone mineral density changes during the menopause transition in a multiethnic cohort of women | Q36494395 |
| | A high incidence of vertebral fracture in women with breast cancer | Q36617488 |
| | Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline | Q36778558 |
| | Screening, prevention, detection, and treatment of cancer therapy-induced bone loss in patients with breast cancer | Q36847010 |
| | Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel | Q36955961 |
| | Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review | Q36981339 |
| | Cancer treatment-induced bone loss: pathophysiology and clinical perspectives | Q37096405 |
| | Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors | Q37119183 |
| | Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy | Q37121645 |
| | Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer | Q37121724 |
| | Zoledronic acid for cancer therapy--induced and postmenopausal bone loss | Q37123420 |
| | Practical guidance for the management of aromatase inhibitor-associated bone loss | Q37151578 |
| | Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer | Q37155592 |
| | Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8. | Q37520291 |
| | Estrogens as regulators of bone health in men. | Q37520591 |
| | Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. | Q37532912 |
| | Impact of androgen deprivation therapy on cardiovascular disease and diabetes. | Q37583719 |
| | Prevention and treatment of side-effects of systemic treatment: bone loss | Q37799925 |
| | EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease | Q37807744 |
| | Interpretation and use of FRAX in clinical practice | Q37903748 |
| | Mortality after all major types of osteoporotic fracture in men and women: an observational study. | Q39490012 |
| | Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results | Q39692137 |
| | Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. | Q40263627 |
| | Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds | Q40660025 |
| | Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial | Q41489196 |
| | The crippling consequences of fractures and their impact on quality of life | Q41597014 |
| | Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study | Q41904942 |
| | Changes in body composition during androgen deprivation therapy for prostate cancer | Q42166232 |
| | HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped | Q42619667 |
| | Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours | Q42640096 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 287-303 | |
| P577 | publication date | 2012-08-16 | |
| P1433 | published in | Clinical Medicine Insights: Oncology | Q5133775 |
| P1476 | title | Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab | |
| P478 | volume | 6 | |